Complement component 4

Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression

Retrieved on: 
Wednesday, March 29, 2023

from Memorial Sloan Kettering Cancer Center found previously unknown associations between four protein isoforms and non-small cell lung cancer (NSCLC) progression, constituting potential novel, disease-relevant biomarkers, or therapeutic targets.

Key Points: 
  • from Memorial Sloan Kettering Cancer Center found previously unknown associations between four protein isoforms and non-small cell lung cancer (NSCLC) progression, constituting potential novel, disease-relevant biomarkers, or therapeutic targets.
  • Importantly, the identified NSCLC-associated protein isoforms comprise structural variants of proteins that arise from distinct but related mRNAs produced from the same gene through the process of alternative splicing.
  • Notably, discovery and quantification of such protein variants in a complex biological sample requires deep, unbiased interrogation of the proteome at peptide-level resolution.
  • The Proteograph Product Suite makes it easy to add unbiased, deep, rapid proteomics studies at scale to any lab.

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

Retrieved on: 
Tuesday, June 7, 2022

BRISBANE, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced promising, final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease (HD).

Key Points: 
  • Annexons unique approach to tackle HD targets C1q, the initiating molecule of the classical complement pathway, to slow or halt classical complement diseases.
  • ANX005 is designed to fully block C1q and the entire classical complement pathway with the aim of preserving functioning synapses to slow or halt neurodegeneration.
  • The apparent continued stabilization of clinical function over nine months is notable, and generally not expected in a progressive disease like HD.
  • The study enrolled a total of 28 patients, of whom 23 completed both six-months of treatment and subsequent three-month follow-up period.

Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment

Retrieved on: 
Tuesday, January 4, 2022

Annexon is developing ANX005, its lead monoclonal antibody candidate, for the treatment of a range of complement-mediated disorders, including HD.

Key Points: 
  • Annexon is developing ANX005, its lead monoclonal antibody candidate, for the treatment of a range of complement-mediated disorders, including HD.
  • NfL levels observed after six months of treatment remained generally consistent and were comparable to NfL levels described in published natural history data for HD patients.
  • In the HD trial, five patients discontinued ANX005 treatment, three of whom discontinued due to a drug-related AE.
  • Pending results from the full dataset, Annexon plans to evaluate the opportunity for a Phase 3 trial of ANX005 in HD patients.

Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences

Retrieved on: 
Friday, October 29, 2021

Catalyst will provide an overview of the Companys ProTUNE platform, and its ability to engineer Complement Factor I (CFI) for potency and specificity in complement-mediated disorders.

Key Points: 
  • Catalyst will provide an overview of the Companys ProTUNE platform, and its ability to engineer Complement Factor I (CFI) for potency and specificity in complement-mediated disorders.
  • "We are excited that the ProTUNE platform and specifically the C3b/C4b degraders are demonstrating the potential to be used for precision medicine, in multiple complement-related indications, saidGrant Blouse, Ph.D., chief scientific officer of Catalyst.
  • Were looking forward to providing additional updates on our complement discovery programs as well as on CB 4332, our enhanced CFI protease for CFI deficiency expected to enter the clinic in 2022.
  • Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.

Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics

Retrieved on: 
Thursday, September 9, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT), being held September 8-13, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT), being held September 8-13, 2021.
  • The oral presentation, Complement Factor I (CFI) as a Protease Medicine: Engineered New Therapeutics for Complement-Mediated Disorders, was presented by Natacha Le Moan, Ph.D., executive director, translational research, Catalyst Biosciences.
  • CB 4332 is Catalysts wholly owned, first-in-class, enhanced CFI, intended for prophylactic subcutaneous (SQ) administration in individuals with CFI deficiency.
  • Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.

C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021

The in vitro results presented confirmed that treatment with CFT7455 results in deep, rapid degradation of IKZF1/3 proteins, generating apoptotic cell death.

Key Points: 
  • The in vitro results presented confirmed that treatment with CFT7455 results in deep, rapid degradation of IKZF1/3 proteins, generating apoptotic cell death.
  • Net loss per share for the first quarter of 2021 was $0.49, compared to $9.59 for the first quarter of 2020.
  • To learn more about C4 Therapeutics, visit www.C4Therapeutics.com .\nThis press release contains \xe2\x80\x9cforward-looking statements\xe2\x80\x9d of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995.
  • All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.\n"

Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity

Retrieved on: 
Thursday, October 15, 2020

CRP, C-reactive protein; IL-6, interleukin 6; LDH, lactate dehydrogenase; TCC, terminal complement complex; ULN, upper limit of normal.

Key Points: 
  • CRP, C-reactive protein; IL-6, interleukin 6; LDH, lactate dehydrogenase; TCC, terminal complement complex; ULN, upper limit of normal.
  • Apellis also announced preliminary results from the first part of the interventional Phase 1/2 study of APL-9 in patients with severe COVID-19.
  • The observational exploratory study evaluated the relationship between markers of complement activation and disease severity in 41 patients with COVID-19.
  • The primary objective of the observational study was to quantify systemic concentrations of the complement activation products Bb, C3a, C4a and terminal complement complex (TCC) and correlate them to COVID-19 severity.

C4 Systems Appoints Avionics Advisor to Expand and Serve U.S. Market

Retrieved on: 
Wednesday, October 14, 2020

C4 Systems appoints Larry Liss to its advisory board to assist C4S in penetrating the U.S. aviation market.

Key Points: 
  • C4 Systems appoints Larry Liss to its advisory board to assist C4S in penetrating the U.S. aviation market.
  • Liss, a highly decorated U.S. Army captain, flew more than 650 combat missions as a helicopter pilot in Vietnam.
  • C4 Systems is disrupting the $100 billion Aerospace modernization market, through innovative software & augmented reality technology.
  • For more information on C4 Systems, please visit https://www.c4systems.co.il/ or watch the following video .